JP2019532067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532067A5 JP2019532067A5 JP2019519978A JP2019519978A JP2019532067A5 JP 2019532067 A5 JP2019532067 A5 JP 2019532067A5 JP 2019519978 A JP2019519978 A JP 2019519978A JP 2019519978 A JP2019519978 A JP 2019519978A JP 2019532067 A5 JP2019532067 A5 JP 2019532067A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- independently
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 150000002828 nitro derivatives Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 0 CC(C)(C)CC(C(O)=*)N Chemical compound CC(C)(C)CC(C(O)=*)N 0.000 description 3
- MYFMARDICOWMQP-UHFFFAOYSA-N CC(C)CC(C(O)=O)NC(CCC(C(O)=O)N)=O Chemical compound CC(C)CC(C(O)=O)NC(CCC(C(O)=O)N)=O MYFMARDICOWMQP-UHFFFAOYSA-N 0.000 description 1
- WZVZUKROCHDMDT-UHFFFAOYSA-N CCC(C(O)=O)NC(C)=O Chemical compound CCC(C(O)=O)NC(C)=O WZVZUKROCHDMDT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408182P | 2016-10-14 | 2016-10-14 | |
| US62/408,182 | 2016-10-14 | ||
| PCT/US2017/056454 WO2018071741A1 (en) | 2016-10-14 | 2017-10-13 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532067A JP2019532067A (ja) | 2019-11-07 |
| JP2019532067A5 true JP2019532067A5 (enExample) | 2020-11-26 |
| JP7332469B2 JP7332469B2 (ja) | 2023-08-23 |
Family
ID=61906413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519978A Active JP7332469B2 (ja) | 2016-10-14 | 2017-10-13 | スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11008287B2 (enExample) |
| EP (1) | EP3526195A4 (enExample) |
| JP (1) | JP7332469B2 (enExample) |
| KR (1) | KR20190128619A (enExample) |
| CN (1) | CN110352190A (enExample) |
| AU (2) | AU2017342436C1 (enExample) |
| BR (1) | BR112019007453A2 (enExample) |
| CA (1) | CA3040479A1 (enExample) |
| EA (1) | EA201990949A1 (enExample) |
| IL (1) | IL265970B (enExample) |
| MX (1) | MX2019004280A (enExample) |
| SG (1) | SG11201903312VA (enExample) |
| WO (1) | WO2018071741A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| DK3402480T3 (da) | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
| WO2018071741A1 (en) | 2016-10-14 | 2018-04-19 | Epicentrix, Inc. | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| WO2022266365A1 (en) * | 2021-06-16 | 2022-12-22 | Epicentrx, Inc. | Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disorders |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2978453A (en) | 1956-12-12 | 1961-04-04 | Aerojet General Co | 3, 3, 5, 5-tetranitropiperidine |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5511509A (en) | 1978-07-07 | 1980-01-26 | Toomasu Gorudon Robaato | Cancer therapy |
| US4935450A (en) | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| GB8728418D0 (en) | 1987-12-04 | 1988-01-13 | Jenkins T C | Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5693794A (en) | 1988-09-30 | 1997-12-02 | The United States Of America As Represented By The Secretary Of The Navy | Caged polynitramine compound |
| JP2659614B2 (ja) | 1990-11-13 | 1997-09-30 | 株式会社日立製作所 | 表示制御装置 |
| TW198712B (enExample) * | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5679777A (en) | 1991-11-08 | 1997-10-21 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5336784A (en) | 1993-06-07 | 1994-08-09 | The Regents Of The University Of California | Synthesis of 1,3,3-trinitroazetidine |
| PT719145E (pt) | 1994-05-27 | 2001-01-31 | Cellegy Pharma Inc | Composicao dadora de oxido nitrico para tratamento de desordens anais |
| IL117473A (en) | 1995-03-14 | 2001-08-26 | Siemens Ag | Ultrasonic atomizer device with removable precision dosating unit |
| EP0814861B1 (en) | 1995-03-14 | 2002-06-05 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
| WO1996036602A1 (en) | 1995-05-15 | 1996-11-21 | The United States Of America | Adnaz, compositions and processes |
| US5580988A (en) | 1995-05-15 | 1996-12-03 | The United States Of America As Represented By The Secretary Of The Army | Substituted azetidines and processes of using them |
| US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
| CA2268098A1 (en) * | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | Aspartate ester inhibitors of interleukin-1.beta. converting enzyme |
| CA2268768A1 (en) | 1996-10-15 | 1998-04-23 | Eastman Chemical Company | Explosive formulations |
| GB9720797D0 (en) | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| US6056966A (en) | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
| US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6391911B1 (en) | 1999-02-26 | 2002-05-21 | Robert E. Bases | Coadministration of lucanthone and radiation for treatment of cancer |
| US20020077276A1 (en) | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| HUP0300413A2 (hu) | 2000-04-10 | 2003-06-28 | Pfizer Products Inc. | Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US6861530B2 (en) | 2000-07-07 | 2005-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Piperidine derivatives |
| DE10111049A1 (de) | 2001-03-06 | 2002-09-12 | Beiersdorf Ag | Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP2005539089A (ja) | 2002-07-03 | 2005-12-22 | ニトロメッド インコーポレーティッド | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 |
| EP1556056A4 (en) | 2002-10-07 | 2008-08-06 | Radiorx Inc | X-Nitro Compounds, Pharmaceutical Compositions And Their Uses |
| WO2004098538A2 (en) | 2003-03-13 | 2004-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
| ES2358801T3 (es) | 2003-06-25 | 2011-05-13 | Je Il Pharmaceutical Co., Ltd. | Derivados tricíclicos o sales farmacéuticamente aceptables de los mismos, sus preparaciones y composiciones farmacéuticas que los contienen. |
| WO2005004884A2 (en) | 2003-07-09 | 2005-01-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| GB0326047D0 (en) | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
| JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| AU2006228957A1 (en) * | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| EP1996550A2 (en) | 2005-09-27 | 2008-12-03 | Novartis AG | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US8122281B2 (en) | 2007-04-13 | 2012-02-21 | International Business Machines Corporation | System and method for dependent failure-aware allocation of distributed data-processing systems |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| US20120149678A1 (en) | 2010-12-09 | 2012-06-14 | Oronsky Bryan T | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto |
| US8664247B2 (en) | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| WO2013052164A1 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Organonitro thioether compounds and medical uses thereof |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| DK3402480T3 (da) | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
| WO2018071741A1 (en) | 2016-10-14 | 2018-04-19 | Epicentrix, Inc. | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
-
2017
- 2017-10-13 WO PCT/US2017/056454 patent/WO2018071741A1/en not_active Ceased
- 2017-10-13 EP EP17859688.8A patent/EP3526195A4/en not_active Withdrawn
- 2017-10-13 AU AU2017342436A patent/AU2017342436C1/en not_active Ceased
- 2017-10-13 EA EA201990949A patent/EA201990949A1/ru unknown
- 2017-10-13 US US16/341,538 patent/US11008287B2/en active Active
- 2017-10-13 KR KR1020197013789A patent/KR20190128619A/ko not_active Withdrawn
- 2017-10-13 SG SG11201903312VA patent/SG11201903312VA/en unknown
- 2017-10-13 MX MX2019004280A patent/MX2019004280A/es unknown
- 2017-10-13 CN CN201780077202.8A patent/CN110352190A/zh active Pending
- 2017-10-13 BR BR112019007453A patent/BR112019007453A2/pt not_active Application Discontinuation
- 2017-10-13 CA CA3040479A patent/CA3040479A1/en active Pending
- 2017-10-13 JP JP2019519978A patent/JP7332469B2/ja active Active
-
2019
- 2019-04-11 IL IL265970A patent/IL265970B/en unknown
-
2022
- 2022-05-12 AU AU2022203169A patent/AU2022203169B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| JP2017533968A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| JP2013532652A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| JP2012532137A5 (enExample) | ||
| MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PH12014500326B1 (en) | Heterocyclic derivative and pharmaceutical drug | |
| JP2011132222A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP2016516043A5 (enExample) | ||
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| JP2015504091A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2019513745A5 (enExample) | ||
| JP2019521958A5 (enExample) | ||
| AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek |